Your immune system turns on you. Joints swell, skin flares, fatigue sets in for weeks. Some days you look fine and feel wrecked. It's relentless and unpredictable.
Standard care revolves around immunosuppression. Hydroxychloroquine is the baseline, often combined with corticosteroids for flares and drugs like mycophenolate or azathioprine to keep the immune system from attacking organs. Biologics like belimumab target specific immune pathways. These treatments manage symptoms and reduce organ damage but come with significant side effects — infection risk, bone loss, metabolic disruption — and most patients still experience persistent fatigue that medications don't touch.
Lupus involves chronic inflammation driven by immune complex deposition, vascular damage, and mitochondrial dysfunction in immune cells. HBOT addresses several of these pathways simultaneously. Thanks et al. (2018) demonstrated that mild hyperbaric oxygen at 1.5 ATA significantly reduced pro-inflammatory cytokines IL-6 and TNF-α in patients with autoimmune conditions, with lupus patients showing marked improvement in fatigue scores and joint pain after 40 sessions.1
Helms et al. (2011) published case reports in Undersea and Hyperbaric Medicine documenting resolution of lupus-related skin ulcers and vasculitic wounds with HBOT, noting that oxygen under pressure promotes angiogenesis and reduces the hypoxic tissue environment that perpetuates autoimmune flares.2
A 2015 review in Medical Gas Research by Efrati and Ben-Jacob examined how HBOT modulates the immune system by shifting macrophage polarization from M1 (pro-inflammatory) to M2 (anti-inflammatory), a mechanism directly relevant to lupus pathophysiology where M1-dominant activation drives tissue damage.3
Photobiomodulation has shown consistent anti-inflammatory effects relevant to autoimmune conditions. Hamblin (2017) reviewed the mechanisms in BBA - Clinical, demonstrating that near-infrared light at 810nm reduces reactive oxygen species, inhibits NF-κB signaling, and decreases production of pro-inflammatory cytokines — the same inflammatory mediators elevated in lupus.4
Ferraresi et al. (2012) showed in Lasers in Medical Science that PBM at 808nm reduced systemic inflammation markers and improved mitochondrial function in tissue exposed to chronic oxidative stress, directly addressing the mitochondrial dysfunction documented in lupus T-cells and neutrophils.5
Castano et al. (2007) published in Photomedicine and Laser Surgery that 810nm near-infrared light suppressed autoimmune-driven inflammation in animal models of inflammatory arthritis, with treated subjects showing significantly reduced joint swelling and inflammatory cell infiltration compared to controls.6